---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-193404"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:06:06.256456+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection

## Summary
- Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).
- Topline data expected in second half of 2026; trial to enroll ~630 patients.
- Phase 2 ARCHER: ANX007 reduced ≥15-letter BCVA loss to 5.6% vs sham 21.3% (p=0.0021).
- Structural protection: up to 60% photoreceptor preservation in central fovea (p=0.0319).
- FDA/EMA aligned on BCVA as primary endpoint; EU PRIME and US Fast Track designations.

## SEC filing metadata
- accession: 0001193125-24-193404
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524193404/0001193125-24-193404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524193404/d833325d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-193404
- JSON: https://secwatch.observer/filing/0001193125-24-193404.json
- Plain text: https://secwatch.observer/filing/0001193125-24-193404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.